Subcutaneous terbutaline use in CKD to reduce potassium concentrations

American Journal of Kidney Diseases

Volumn 45, Issue 6, 2005, Pages 1040-1045

  Sowinski, Kevin M ^a   Cronin, Donald ^b   Mueller, Bruce A ^b   Kraus, Michael A ^b  

^a PURDUE UNIVERSITY   (United States)

^b NONE

Author keywords

Chronic kidney disease (CKD); Hyperkalemia; Terbutaline

Indexed keywords

POTASSIUM; TERBUTALINE;

ADULT; ARTICLE; BLOOD SAMPLING; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EVALUATION; FEMALE; HEART RATE; HEMODIALYSIS; HUMAN; HYPERKALEMIA; MALE; POTASSIUM BLOOD LEVEL;

ADRENERGIC BETA-AGONISTS; ADULT; BODY WEIGHT; FEMALE; HEART RATE; HUMANS; HYPERKALEMIA; INJECTIONS, SUBCUTANEOUS; KIDNEY DISEASES; MALE; MIDDLE AGED; POTASSIUM; RECEPTORS, ADRENERGIC, BETA-2; RENAL DIALYSIS; TERBUTALINE;

EID: 20444404996     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2005.02.016     Document Type: Article

References (18)

1. US Renal Data System USRDS 2002 Annual Data Report 2002 The National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases Bethesda, MD
2. M.M. Salem, R.M. Rosa, D.C. Batlle Extrarenal potassium tolerance in chronic renal failure Implications for the treatment of acute hyperkalemia Am J Kidney Dis 18 1991 421 440
3. M. Allon Treatment and prevention of hyperkalemia in end-stage renal disease Kidney Int 43 1993 1197 1209
4. J. Fernandez, J.R. Oster, G.O. Perez Impaired extrarenal disposal of an acute oral potassium load in patients with end stage renal disease on chronic hemodialysis Miner Electrolyte Metab 12 1986 125 129
5. C.L. Stemmer, G.O. Perez, J.R. Oster Impairment of beta 2-adrenoceptor-stimulated potassium uptake in end-stage renal disease J Clin Pharmacol 27 1987 628 631
6. J. D'Silva The action of adrenaline on serum potassium J Physiol (Lond) 82 1934 393 398
7. M.J. Brown, D.C. Brown, M.B. Murphy Hypokalemia from beta2-receptor stimulation by circulating epinephrine N Engl J Med 309 1983 1414 1419
8. R.M. Rosa, P. Silva, J.B. Young Adrenergic modulation of extrarenal potassium disposal N Engl J Med 302 1980 431 434
9. R. Jonkers, C.J. van Boxtel, R.P. Koopmans, B. Oosterhuis A nonsteady-state agonist antagonist interaction model using plasma potassium concentrations to quantify the beta-2 selectivity of beta blockers J Pharmacol Exp Ther 249 1989 297 302
10. R. Jonkers, C.J. van Boxtel, B. Oosterhuis Beta-2-adrenoceptor-mediated hypokalemia and its abolishment by oxprenolol Clin Pharmacol Ther 42 1987 627 633
11. S. Rolf Smith, M.J. Kendall, D.J. Worthington, R. Holder Can the biochemical responses to a beta 2-adrenoceptor stimulant be used to assess the selectivity of beta-adrenoceptor blockers? Br J Clin Pharmacol 16 1983 557 560
12. R.A. DeFronzo, M. Bia, G. Birkhead Epinephrine and potassium homeostasis Kidney Int 20 1981 83 91
13. M. Allon, R. Dunlay, C. Copkney Nebulized albuterol for acute hyperkalemia in patients on hemodialysis Ann Intern Med 110 1989 426 429
14. M. Allon, C. Copkney Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients Kidney Int 38 1990 869 872
15. J. Montoliu, J. Almirall, E. Ponz, J.M. Campistol, L. Revert Treatment of hyperkalaemia in renal failure with salbutamol inhalation J Intern Med 228 1990 35 37
16. J. Montoliu, X.M. Lens, L. Revert Potassium-lowering effect of albuterol for hyperkalemia in renal failure Arch Intern Med 147 1987 713 717
17. H.H. Liou, S.S. Chiang, S.C. Wu Hypokalemic effects of intravenous infusion or nebulization of salbutamol in patients with chronic renal failure Comparative study Am J Kidney Dis 23 1994 266 271
18. A. Mandelberg, Z. Krupnik, S. Houri Salbutamol metered-dose inhaler with spacer for hyperkalemia: How fast? How safe? Chest 115 1999 617 622